Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

Table 3 Correlation between clinicopathological variables and radiologic response rate

Variables		No. of Pts	Responders (RR %)	p-value*
Age	< 50 ≥ 50	102 43	69 (67.6) 31 (72.1)	0.597
Performance	ECOG 0–1 ECOG 2	139 6	95 (68.3) 5 (83.3)	0.666
Initial clinical stage	IIA, IIB, IIIA IIIB, IIIC	93 52	64 (68.8) 36 (69.2)	0.959
pCR	No	134	89 (66.4)	0.018
	Yes	11	11 (100.0)
Nuclear grade	I, II	41	22 (53.7)	0.069
	III	87	61 (70.1)
	Unknown	17	-
Histologic grade	I, II	39	24 (61.5)	0.741
	III	82	53 (64.6)
	Unknown	24	-
ER	Positive	64	41 (64.1)	0.257
	Negative	81	59 (72.8)
PR	Positive	44	28 (63.6)	0.360
	Negative	101	72 (71.3)
bcl-2	Positive	63	45 (71.4)	0.749
	Negative	74	51 (68.9)
	Unknown	8	-
Ki-67	Low expression^#	56	34 (60.7)	0.066
	High expression	85	64 (75.3)
	Unknown	4	-
p53	Low expression^#	67	43 (64.2)	0.219
	High expression	76	56 (73.7)
	Unknown	2	-
c-erbB2	0/+/++	107	76 (71.0)	0.368
	+++	38	24 (63.2)
Triple negative	No	98	61 (62.2)	0.012
	Yes	47	39 (83.0)

RR, response rate; pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor.
*based on Pearson's χ² test (using Fisher's exact test if N ≤ 5).
^#Ki-67 with ≤ 5% and p53 with <25% were considered as low expression.

ISSN: 1471-2407